Life Sciences

If the United States is serious about maintaining its leadership in biopharmaceuticals, then it’s time for policymakers to articulate and embrace a robust sectoral competitiveness strategy.
Life Sciences
Check a box to narrow search for individual content items that cover numerous issues.
April 29, 2016
The unintended exploitation of Bayh-Dole “march-in” rights would significantly harm biomedical innovation, writes Stephen Ezell in Innovation Files.
April 27, 2016
Nigel Cory writes in Innovation Files that Russia is moving away from world trade rules with its increasing use of data localization and mercantilist trade policies.
April 7, 2016
This report ranks 56 countries based on the extent to which their domestic policies support global biopharmaceutical innovation.
April 6, 2016
Rob Atkinson outlines five of the most common myths about America’s system for discovering and developing new drugs on the Huffington Post.
March 10, 2016
Stephen Ezell and Nigel Cory argue in The Hill that the United States should push Canada to change its pharma patent assessment process.
March 9, 2016
U.S. policymakers should reject the false choice between public-sector leadership and private-sector leadership for life sciences innovation. The U.S. leads the world because its system maximizes the strengths of both, writes Rob Atkinson in The Hill.
February 23, 2016
The United States has been the world’s medicine cabinet for too long, and it’s time for the rest of the world to stop free riding and do their share, too, writes Rob Atkinson in Forbes.
February 22, 2016
America’s success in discovering and developing drugs depends on the twin pillars of federal support for scientific research and a strong IP and reimbursement system that promotes private-sector innovation.
February 15, 2016
In testimony to the U.S. ITC, Stephen Ezell explains why biotech is a key driver of both the U.S. economy and global life sciences innovation, and he argues robust IP standards in the TPP will be critical to both.
February 2, 2016
The United States leads the world in the period of data exclusivity it provides to innovators of biologic medicines, writes Adams Nager in Innovation Files.

Pages